Long-term Probability of and Mortality From De Novo Malignancy After Liver Transplantation

Gastroenterology

Volumn 137, Issue 6, 2009, Pages 2010-2017

  Watt, Kymberly D S ^a   Pedersen, Rachel A ^a   Kremers, Walter K ^a   Heimbach, Julie K ^a   Sanchez, William ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ALCOHOL LIVER DISEASE; ARTICLE; FEMALE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SKIN CANCER; SMOKING; SURVIVAL TIME;

EID: 70649096162     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.08.070     Document Type: Article

References (28)

1. Fung J.J., Jain A., Kwak E.J., et al. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 7 suppl 1 (2001) S109-S118
2. Jain A., Marcos A., Reyes J., et al. Tacrolimus for primary liver transplantation: 12 to 15 years' actual follow-up with safety profile. Transplant Proc 37 (2005) 1207-1210
3. Sheil A.G. Malignancy following liver transplantation: a report from the Australian Combined Liver Transplant Registry. Transplant Proc 27 (1995) 1247
4. Lukes D.J., Herlenius G., Rizell M., et al. Late mortality in 679 consecutive liver transplant recipients: the Gothenburg liver transplant experience. Transplant Proc 38 (2006) 2671-2672
5. Xiol X., Guardiola J., Menendez S., et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl 7 (2001) 971-975
6. Rabkin J.M., de La Melena V., Orloff S.L., et al. Late mortality after orthotopic liver transplantation. Am J Surg 181 (2001) 475-479
7. Pruthi J., Medkiff K.A., Esrason K.T., et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 7 (2001) 811-815
8. Herrero J.I., Lucena J.F., Quiroga J., et al. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant 3 (2003) 1407-1412
9. Kelly D.M., Emre S., Guy S.R., et al. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 83 (1998) 1237-1243
10. Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 2 (1996) 52-59
11. Haagsma E.B., Hagens V.E., Schaapveld M., et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 34 (2001) 84-91
12. Jiang Y., Villeneuve P., Fenton S., Schaubel D., Lilly L., and Mao Y. Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl 14 (2008) 1588-1597
13. Wei Y.W., Detre K.M., and Everhart J.E. The NIDDK liver transplantation database. Liver Transpl Surg 3 (1997) 10-22
14. Wiesner R., Lombardero M., Lake J., Everhart J., and Detre K. Liver transplantation for end-stage alcoholic liver disease: an assessment of outcomes. Liver Transpl Surg 3 (1997) 231-239
15. Gooley T., Leisenring W., Crowley J., and Storer B. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18 (1999) 695-706
16. Watt K., Pedersen R., and Charlton M. Long-term causes of mortality post liver transplantation: a multi-centered prospective analysis of the NIDDK database. Liver Transpl 14 (2008) S229 [abstract #568]
17. Yao F.Y., Gautam M., Palese C., et al. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. Clin Transplant 20 (2006) 617-623
18. Catalina M.V., de Diego A., García-Sánchez A., et al. Characterization of de novo malignancies in liver transplantation. Gastroenterol Hepatol 26 (2003) 57-63
19. Saigal S., Norris S., Muiesan P., et al. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 8 (2002) 482-487
20. Sanchez E.Q., Marubashi S., Jung G., et al. De novo tumors after liver transplantation: a single-institution experience. Liver Transpl 8 (2002) 285-291
21. Jain A.B., Yee L.D., Nalesnik M.A., et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 66 (1998) 1193-1200
22. Deeb K., Trump D., and Johnson C. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7 (2007) 684-700
23. Holick M. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81 (2006) 353-373
24. National Cancer Institute. http://seer.cancer.gov Accessed November 3, 2009
25. Sorensen H.T., Friis S., Olsen J.H., et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 28 (1998) 921-925
26. VanderHeide F., Dijkstra G., Porte R., Kleibeuker J., and Haagsma E. Smoking behavior in liver transplant recipients. Liver Transpl 15 (2009) 648-655
27. Graziadei I., Wiesner R., Batts K., et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 29 (1999) 1050-1056
28. Sokol H., Cosnes J., Chazouilleres O., et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 14 (2008) 3497-3503